Recent Posts

Rethinking the Interpretation of Randomized Trials: A Reflection on CLOSURE-AF

A few days ago, the CLOSURE AF Trial was published online at NEJM. It was accompanied by an editorial titled “another overused method in Cardiology”. Friends sent me links to … Continue reading Rethinking the Interpretation of Randomized Trials: A Reflection on CLOSURE-AF

Understanding the ACURATE neo2 TAVI Withdrawal: Key Insights

Boston Scientific has withdrawn the ACURATE neo2 TAVI series, a decision likely reflective of testing challenges rather than the valve’s quality. Prior trials revealed suboptimal performance and increased patient risks, potentially due to operator inexperience and inadequate patient selection. The learning curve for this device may have influenced outcomes, warranting improved trial designs in the future.

If you think PROTECTED TAVR is a NEGATIVE trial, you should read this: Cerebral protection (Sentinel) in TAVI

Pablo Lamelas –PROTECTED TAVR study was presented in TCT 2022, bringing more discussion than ever for the use of Sentinel (cerebral embolic protection, CEP) during TAVR procedures. Many key opinion … Continue reading If you think PROTECTED TAVR is a NEGATIVE trial, you should read this: Cerebral protection (Sentinel) in TAVI

SOLACI/SIAC 2021 Guideline on the use of TAVI vs SAVR in Latin America: Presentation at ICBA Grand Rounds.

Pablo Lamelas – Last Thursday June 24th the first SOLACI/SIAC joint guideline was presented at ICBA Instituto Cardiovascular Rounds. Here we present a summary in English with outstanding faculty, an … Continue reading SOLACI/SIAC 2021 Guideline on the use of TAVI vs SAVR in Latin America: Presentation at ICBA Grand Rounds.